Advances in Radiation Therapy Techniques for Oesophageal Cancer

Oesophageal cancer remains one of the most challenging malignancies to treat, with five-year survival rates still hovering around 20% in many populations. At the recent ISDE 2021 congress, several sessions focused on how modern radiation therapy techniques are reshaping the therapeutic landscape, particularly for patients with locally advanced disease who are not surgical candidates or who opt for organ preservation.

Australia records roughly 1,500 new cases of oesophageal cancer each year, with higher incidence among older men and notable variation between urban and remote communities. Treatment patterns differ between metropolitan centres such as Sydney, Melbourne, and Brisbane and regional hubs like Townsville, Launceston, and Cairns, where access to subspecialty radiation oncology can be limited. These geographic and demographic realities have made technological refinement and tele-oncology collaboration a national priority.

From three-dimensional conformal to intensity-modulated radiotherapy

Three-dimensional conformal radiotherapy has largely given way to intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) in Australian cancer centres. These techniques allow clinicians to sculpt dose distributions around irregular tumour volumes while sparing nearby organs at risk, including the heart, lungs, and spinal cord. For oesophageal tumours that often wrap around mediastinal structures, the improved conformity is clinically meaningful.

Studies presented at the congress confirmed lower rates of grade 3 pneumonitis and pericarditis when IMRT replaced older conformal approaches. Centres in Adelaide and Perth reported similar toxicity profiles in their prospective audits, suggesting that the benefits seen in international trials translate well to local populations.

Image-guided and adaptive radiotherapy in routine practice

Daily cone-beam CT and MR-guided linear accelerators have shifted radiotherapy from a static, plan-and-treat workflow into a dynamic, responsive process. Adaptive radiotherapy, where the treatment plan is recalculated mid-course to account for tumour shrinkage or weight loss, is now standard in several high-volume Australian departments. The Peter MacCallum Cancer Centre in Melbourne has published extensively on MR-guided workflows for upper gastrointestinal malignancies.

For patients with oesophageal cancer, who often lose 5–10% of body weight during treatment, adaptive replanning can prevent under-dosing of residual disease or excessive dose to shrinking lung volumes. The technique also supports tighter margins, which translates directly into fewer side effects during the six-to-seven-week treatment course.

Proton beam therapy access across the country

Proton beam therapy offers superior dose distribution for many thoracic tumours because of the absence of exit dose beyond the Bragg peak. Australian patients have historically travelled overseas, often to the United States or Japan, for this treatment. The opening of the Australian Bragg Centre for Proton Therapy and Research in Adelaide, expected to treat its first patients in coming years, will change that landscape.

Until the local facility is fully operational, clinicians continue to refer selected cases abroad through the Medical Treatment Overseas Program. Indications most often include young patients with curable disease, those with prior radiotherapy to the chest, and individuals whose anatomy places critical organs at high risk of conventional photon toxicity.

Combining radiotherapy with systemic therapies

Concurrent chemoradiation remains the backbone of definitive management for locally advanced squamous cell carcinoma and is increasingly used for adenocarcinoma as part of a trimodality pathway. Recent trials highlighted at ISDE 2021 explored the addition of immune checkpoint inhibitors such as nivolumab and pembrolizumab to standard chemoradiation. The Australian-led TROG 14.01 study and several international counterparts have helped define safe sequencing and dosing.

The goal is to convert initially unresectable disease into operable disease, or to achieve durable locoregional control without surgery. Medical oncologists and radiation oncologists in Canberra, Brisbane, and Hobart now routinely discuss these combinations in joint clinics, ensuring patients receive evidence-based care regardless of where they first present.

Cardiac and pulmonary sparing approaches

Because oesophageal tumours lie close to the heart, cardiotoxicity has emerged as a key driver of long-term mortality after chemoradiation. Heart-sparing IMRT, deep inspiration breath hold, and proton techniques all aim to reduce mean heart dose below established thresholds. Real-time surface-guided radiotherapy, now offered at several Australian private providers including Icon Group and GenesisCare sites, helps maintain reproducibility without invasive markers.

Pulmonary sparing is equally important, particularly for patients with underlying chronic obstructive pulmonary disease common among long-term smokers. Functional lung imaging, including ventilation-perfusion SPECT integrated into treatment planning, is being trialled at the Royal Brisbane and Women's Hospital to identify and avoid irradiated regions of pre-existing lung compromise.

The role of multidisciplinary tumour boards

Every Australian oesophageal cancer patient should have their case discussed at a multidisciplinary meeting that includes surgical, medical, radiation, and gastroenterology input. The Royal Australasian College of Surgeons and the Royal Australian and New Zealand College of Radiologists both endorse this model. Weekly tumour conferences in Sydney's Chris O'Brien Lifehouse and Melbourne's Peter Mac serve as templates for regional centres.

Telehealth links now extend these discussions to Dubbo, Alice Springs, and Broome, allowing regional clinicians to present imaging and pathology in real time. This networked approach has particular value when deciding between definitive chemoradiation and neoadjuvant chemoradiation followed by surgery, a decision that often hinges on nuanced tumour characteristics and patient fitness.

Post-treatment surveillance and patient counselling

Long-term follow-up after definitive chemoradiation includes endoscopic inspection, cross-sectional imaging, and nutritional assessment. Australian guidelines recommend endoscopic surveillance at three months, then every six months for the first two years, and annually thereafter. Patients with persistent dysphagia or new symptoms should be re-evaluated promptly rather than waiting for scheduled review.

Education on what to expect during recovery, including the slow return of swallowing function and the possibility of stricture, helps patients recognise warning signs early. Resources shared through ISDE have recently addressed how to counsel patients about surveillance after radiofrequency ablation, an adjacent topic relevant to many patients with Barrett-related neoplasia who also undergo radiotherapy for synchronous lesions.

For patients completing treatment at an Australian centre, the immediate next step is to confirm a structured follow-up appointment with their radiation oncologist and gastroenterologist before leaving the treatment facility, ideally scheduled within four to six weeks of the final fraction.